INNOVENT BIO: Third-quarter product revenue exceeded RMB 3.3 billion, a year-on-year increase of approximately 40%
INNOVENT BIO announced that in the third quarter of 2025, the company achieved total product revenue exceeding RMB 3.3 billion, a year-on-year increase of approximately 40%. The company maintains a leading position in the field of cancer treatment, with significant advantages in its product portfolio. Major products such as Daborhuzhu have shown steady growth, and the contribution of revenue from innovative products has further increased. The potential of the comprehensive product line is being rapidly released, with significant achievements in market access and channel marketing for products such as XinErMei, XinBiLe, and XinBiMin, leading to accelerated product volume and a significant expansion in revenue contribution
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments